Inquiry Basket
Loading ......
Filter By Product Search for
TRIB2
TRIB2 Full Name
tribbles homolog 2 (Drosophila)
TRIB2 Introduction
TRIB2 encodes an atypical serine/threonine pseudokinase, the second member of the tribbles family of scaffold proteins, which are defined by a kinase-homology domain that has lost catalytic activity but retained a powerful ability to organize other proteins. Rather than phosphorylating substrates directly, TRIB2 acts as an adaptor that recruits selected client proteins to E3 ubiquitin ligases for destruction. Its best-characterized function is to bind the CCAAT/enhancer-binding protein alpha (C/EBPalpha), a master transcription factor of myeloid differentiation, together with the constitutive photomorphogenesis 1 (COP1) ubiquitin ligase. By bridging C/EBPalpha and COP1, TRIB2 promotes K48-linked polyubiquitination and proteasomal degradation of C/EBPalpha, thereby blocking granulocytic maturation and locking hematopoietic progenitors in a self-renewing, immature state. The TRIB2 gene maps to chromosome 2p24.3, a locus frequently amplified in human cancer, and its messenger RNA is induced by inflammatory cytokines and oncogenic stress, positioning TRIB2 as a coincidence detector that links extracellular signals to proteostatic control of lineage-determining transcription factors.
Figure 1. Structure and function of TRIB2 pseudokinase. (Source: Mayoral-Varo V, et al. 2021)
The oncogenic potency of TRIB2 was first established in mouse models, where its expression alone is sufficient to induce acute myelogenous leukemia, and in human acute myeloid leukemia (AML) where high TRIB2 correlates with adverse outcome. Structure-function work showed that both the kinase-homology domain and the COP1-binding motif are essential: disrupting either interface abolishes C/EBPalpha degradation and leukemia induction. Beyond AML, TRIB2 is now implicated across many cancers, where it scaffolds MAPK and AKT signaling and targets additional regulators for ubiquitination in a cell-type-dependent manner. TRIB2 can also confer chemoresistance, as seen in AML driven from granulocyte-macrophage progenitors that overexpress BCL2. These features have reframed tribbles proteins as druggable pseudokinase nodes, and recent structural studies using nanobodies have captured an activated conformation of the TRIB2 domain, opening routes to small-molecule inhibitors that disrupt its scaffolding function. Because TRIB2 itself lacks catalytic activity, such compounds aim to block the protein-protein interfaces that enable C/EBPalpha recruitment rather than to occupy a conventional active site, a strategy that may spare normal differentiated hematopoiesis while silencing the leukemogenic program.
Alternate Names for TRIB2
TRIB2; tribbles homolog 2 (Drosophila); tribbles homolog 2; GS3955; TRB2; C5FW; FLJ57420;
Loading ......
